Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Recursion Pharmaceuticals (RXRX) and AN2 Therapeutics, Inc. (ANTX)

TipRanks01:00 ET · Ratings

BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $12

Moomoo NewsNov 21 05:31 ET · Ratings

Hold Rating Recommended for Recursion Pharmaceuticals Post-Merger With Exscientia: Upside Potential Amidst Clinical Uncertainties

TipRanksNov 21 05:28 ET · Ratings

KeyBanc Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $12

Moomoo NewsNov 20 20:31 ET · Ratings

Cathie Wood's ARK Investment Buys 383K Shares of Recursion Pharmaceuticals Today

TipRanksNov 20 20:06 ET

Recursion Pharmaceuticals Price Target Maintained With a $11.00/Share by Needham

Dow JonesNov 20 12:43 ET · Ratings